Erlotinib Completed Phase 3 Trials for Oral Cancers Prevention

IndicationsStatusPurposePhase
CompletedPrevention3
clinicaltrials.gov IdentifierTitleDrugs
NCT00402779Erlotinib Prevention of Oral Cancer (EPOC)